Evotec and CENTOGENE expand collaboration into Gaucher disease
- CENTOGENE AND EVOTEC INTEND TO IDENTIFY NOVEL DISEASE-MODIFYING TARGETS
- FIRST TARGET SELECTED FOR THE DEVELOPMENT OF A THERAPEUTIC CANDIDATE
- CENTOGENE CONTRIBUTES ACCESS TO ITS GLOBAL PROPRIETARY RARE DISEASE PLATFORM, EVOTEC WILL LEVERAGE ITS PROPRIETARY IPSC PLATFORM AND DRUG DISCOVERY AND DEVELOPMENT EXPERTISE?